Delving into the Latest Updates on Octenidine hydrochloride with Synapse

Overview

Basic Info

Drug Type

Small molecule drug

Synonyms

Octenidine hydrochloride (USAN)

+ [3]

Target-

Action-

Mechanism-

Therapeutic Areas

Infectious Diseases

Active Indication

Gram-Negative Bacterial InfectionsGram-Positive Bacterial Infections

Inactive Indication-

Originator Organization-

Active Organization-

Inactive Organization-

License Organization-

Drug Highest PhaseApproved

First Approval Date-

Regulation-

Login to view timeline

Structure/Sequence

Molecular FormulaC36H62N4

InChIKeyZVXNYZWXUADSRV-UHFFFAOYSA-N

CAS Registry71251-02-0

View All Structures (2)

This parallel-group, pilot study will test the hypothesis that the adjunctive use of a thermosensitive gel containing Hyaluronic Acid (HA) and Octenidine to non-surgical periodontal treatment (NSPT) will be able to modulate the early wound healing events. This will be assessed through the expression of specific gingival crevicular fluid markers, as well as by changes in gingival blood flow (assessed by laser speckle contrast imaging), bacterial load, soft tissues contour, clinical parameters and patient-reported outcomes.
The study will involve up to 26 patients and will take place at the Centre for Oral Clinical Research (COCR), at the Institute of Dentistry, Faculty of Medicine and Dentistry, Queen Mary University of London under The Royal London Dental Hospital, Barts Health NHS Trust. Patients will be randomised to receive either NSPT alone or NSPT+ HA and Octenidine gel, and will be followed up to 3 months after treatment.
The study will consist of 7- 8 visits.

Start Date01 Sep 2025

Sponsor / Collaborator

Queen Mary University of London

NCT05647252

/ CompletedPhase 3IIT

General Skin and Nasal Decolonization With Octenisan® Set Be-fore and After Elective Orthopedic Surgery in Selected Patients at Elevated Risk for Revision Surgery and Surgical Site Infections

The general decolonization of the human body surface by industrial antiseptic agents, before elective surgery is recommended by the World Health Organization (WHO).
A specific randomized-controlled trial specifically among high-risk adult orthopedic patients for infection has not been performed.
In this single-center, prospective, randomized, and controlled superiority trial, which is planned over a period of two years, we target on an orthopedic patient population with an elevated risk for revision surgery and surgical site infections

Start Date27 Feb 2023

Sponsor / Collaborator

The University Hospital Balgrist

NCT04172363

/ WithdrawnPhase 3IIT

Clinical Relevance of the Antimicrobial Resistance Testing in the Treatment of Chronic Wounds With Antiseptics

The study objective is to improve the current and local standard antiseptic treatment by adjusting the antiseptic agent to the antimicrobial resistance testing result, accordingly. Currently, resistance testing will only be performed for the treatment with antibiotics.

Start Date22 Jul 2020

Sponsor / Collaborator

RWTH Aachen University

100 Clinical Results associated with Octenidine hydrochloride

Login to view more data

100 Translational Medicine associated with Octenidine hydrochloride

Login to view more data

100 Patents (Medical) associated with Octenidine hydrochloride

Login to view more data

504

Literatures (Medical) associated with Octenidine hydrochloride

14 Apr 2025·ChemMedChem

Expanding the Variety of Pyridinium‐Based Bis‐QACs with Antimicrobial Properties: Investigation into Linker Structure‐Activity Correlation

Article

Author: Son, Elizabeth ; Tyurina, Alexandra N. ; Frolov, Nikita A. ; Tyutin, Alexander A. ; Saverina, Evgeniya A. ; Vereshchagin, Anatoly N. ; Seferyan, Mary A. ; Detusheva, Elena V.

AbstractFor decades quaternary ammonium compounds (QACs) have served as main component of a top antiseptic and disinfectant compositions. Among them, bis‐QACs are the most prominent and effective class of biocides. Although mono‐QACs still dominate the antiseptic market, their activity against Gram‐negative bacteria is largely inferior to bis‐QACs. Moreover, the new wave of bacterial resistance during the COVID‐19 pandemic is threatening the efficiency of popular antiseptics. Therefore, the requirement for novel biocides is urgent. Reported here is a unified and simple two‐step synthesis to achieve novel biocide's architectures with aromatic linkers. Thus, a series of 14 bis‐QACs have been prepared using an Ullman‐type reaction following by N‐alkylation. The most prominent compounds showed strong bioactivity against a panel of nineteen microbial pathogens, multi‐resistant bacterial ESKAPEE strains, fungi and biofilms, including strains, which acquired resistance during COVID‐19 in 2021. Moreover, significant improvements in antibiofilm action were observed, where bis‐QACs 5 c and 6 a outperformed gold standard pyridinium antiseptic octenidine. These findings will serve as a good basis for further studies of bis‐QACs architectures as highly effective biocides.

01 Apr 2025·Journal of Wound Care

Case series 4

Article

Author: Phua, Sheryl ; Cheong, Cherry ; Yong, Enming ; Chew, Tiffany

These two case studies describe the use of Octenisept® in diabetic foot ulcers at a tertiary referral hospital in Singapore

01 Apr 2025·Journal of Wound Care

Case series 1

Article

Author: Hitalla, Rhyan

These two case studies describe the use of Octenisept® in hard-to-heal wounds in a hospital network in the Philippines.

100 Deals associated with Octenidine hydrochloride

Login to view more data